STT3B

Across TCGA pan-cancer cohorts, STT3B mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated STT3B data layer compared with 28 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STT3B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STT3B expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where STT3B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	III,IV	0.500	0.844	.002	41	view →
HNSC	DFS	Quartile	III,IV	0.777	0.489	.002	19	view →
PDAC	DFS	Quartile	All	0.342	0.532	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

STT3B–CCRCC (DFS)

Open the CCRCC breakdown →